Last reviewed · How we verify
NCT06347939: MECRIS
Mediastinal EBUS Cryobiopsy Study In Sweden
trial testing Mediastinal lymph nodes cryobiopsies in Mediastinal Lymphadenopathy in 200 participants. Currently enrolling.
1 April 2026
Quick facts
| Lead sponsor | Region Skane |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 1 April 2024 |
| Primary completion | 1 April 2026 |
| Estimated completion | 31 December 2028 |
| Sites | 2 locations across Sweden |
Drugs / interventions tested
- Mediastinal lymph nodes cryobiopsies
Conditions studied
- Mediastinal Lymphadenopathy — all drugs for Mediastinal Lymphadenopathy →
- Lung Cancer — all drugs for Lung Cancer →
- Sarcoidosis — all drugs for Sarcoidosis →
- Lymphoma — all drugs for Lymphoma →
Sponsor
Region Skane — full company profile →
Who can join
18 and older, any sex, with Mediastinal Lymphadenopathy or Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a prospective observational non-randomized clinical trial where all the participitants undergo the same procedure and every participitant's samples are compared to each other. The investigators conduct EBUS TBNA and EBUS TBMCB on all the study participants.The cryobiopsy samples are numbered to evaluate the number of biopsies needed to reach a definite diagnosis and to assess the added value of every sample taken from the same participitant. Every participitant's own samples are compared to each other and added value of EBUS TBMCB is defined as the difference in diagnostic yield between the EBUS TBNA alone and the combination of EBUS TBNA with EBUS TBMCB. Diagnostic yield is defined as the efficacy of the investigation module in reaching a definite diagnosis (percentage of cases with a definite diagnosis). Follow up four weeks after the procedure to assess the risk for postoperative complications.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06347939
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Mediastinal Lymphadenopathy
Currently open trials in the same condition.
- NCT07301697 — Safety and Performance Profile of Cryobiopsy in Bronchial Endoscopy · NA · recruiting
Other Region Skane trials
Trials by the same sponsor.
- NCT07511673 — The Study is a Randomised Clinical Trial (RCT) to Test if Preoperative Dental Screening is Superior to no Preoperative D · NA · not yet recruiting
- NCT07169747 — Safety, Therapeutic Potential, and Mechanisms of Two Psilocybin Doses, Administered With Psychological Support in Young · Phase 2 · recruiting
- NCT07494669 — Proteomics and Physiological Parameters Predicting Complications After Colorectal Cancer Surgery · not yet recruiting
- NCT07462351 — System-integrated Point-of-Care Ultrasound in Breast Cancer Screening · NA · recruiting
- NCT06975696 — Fusion Imaging in Endovascular Thrombectomy for Acute Ischemic Stroke · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06347939 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Region Skane
- Last refreshed: 17 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06347939.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing